I think this is a very important slide from the last trial results presentation, showing that control patients who received dexamethasone showed no survival benefit. But once treated with Remestemcel-L + dexamethasone, a significant survival benefit of 75% at day 60 and 77% at day 90 was observed (in patients<65).
No treatment for ARDS has ever shown such a significant mortality reduction in any patient population. These are the sickest Covid-19 patients who are in ICU on mechanical ventilation who now have an 86% chance of survival compared to just 55% with current SOC.
I think this is a very important slide from the last trial...
-
- There are more pages in this discussion • 66 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
-0.040(3.76%) |
Mkt cap ! $1.170B | |||
| Open | High | Low | Value | Volume |
| $1.07 | $1.07 | $1.01 | $13.19M | 12.81M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 61090 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 239558 | 5 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |